Bavarian Nordic initiates phase II trial for Covid-19 vaccine

In a long-awaited phase II trial, Bavarian Nordic starts testing the efficacy of its Covid-19 vaccine for reinforcing existing immunity in persons either previously vaccinated or infected.
Photo: Bavarian Nordic / PR
Photo: Bavarian Nordic / PR

After having recently published promising data for its ABNCoV2 vaccine against Covid-19, Bavarian Nordic now begins a phase II trial for its candidate, Bavarian informs in a press release Monday morning.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading